Collateral sensitivity constrains resistance evolution of the CTX-M-15 β-lactamase.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
06 02 2019
Historique:
received: 22 10 2018
accepted: 15 01 2019
entrez: 8 2 2019
pubmed: 8 2 2019
medline: 12 4 2019
Statut: epublish

Résumé

Antibiotic resistance is a major challenge to global public health. Discovery of new antibiotics is slow and to ensure proper treatment of bacterial infections new strategies are needed. One way to curb the development of antibiotic resistance is to design drug combinations where the development of resistance against one drug leads to collateral sensitivity to the other drug. Here we study collateral sensitivity patterns of the globally distributed extended-spectrum β-lactamase CTX-M-15, and find three non-synonymous mutations with increased resistance against mecillinam or piperacillin-tazobactam that simultaneously confer full susceptibility to several cephalosporin drugs. We show in vitro and in mice that a combination of mecillinam and cefotaxime eliminates both wild-type and resistant CTX-M-15. Our results indicate that mecillinam and cefotaxime in combination constrain resistance evolution of CTX-M-15, and illustrate how drug combinations can be rationally designed to limit the resistance evolution of horizontally transferred genes by exploiting collateral sensitivity patterns.

Identifiants

pubmed: 30728359
doi: 10.1038/s41467-019-08529-y
pii: 10.1038/s41467-019-08529-y
pmc: PMC6365502
doi:

Substances chimiques

Anti-Bacterial Agents 0
Drug Combinations 0
beta-Lactams 0
beta-lactamase CTX-M-15 EC 3.5.2.-
beta-Lactamases EC 3.5.2.6
Cefotaxime N2GI8B1GK7
Amdinocillin V10579P3QZ

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

618

Références

Protein Eng. 2003 Jun;16(6):451-7
pubmed: 12874379
J Antimicrob Chemother. 2017 Aug 1;72(8):2145-2155
pubmed: 28541467
PLoS Comput Biol. 2010 Jun 03;6(6):e1000796
pubmed: 20532210
Genetics. 2003 Apr;163(4):1237-41
pubmed: 12702671
Nat Rev Genet. 2014 Jul;15(7):480-90
pubmed: 24913663
Methods Mol Biol. 2009;532:397-411
pubmed: 19271198
Nat Rev Microbiol. 2009 Jan;7(1):73-80
pubmed: 19079353
Microbiol Mol Biol Rev. 2010 Sep;74(3):417-33
pubmed: 20805405
PLoS One. 2015 May 06;10(5):e0122283
pubmed: 25946134
Nat Rev Microbiol. 2004 May;2(5):430-5
pubmed: 15100696
Nat Rev Microbiol. 2010 Apr;8(4):260-71
pubmed: 20208551
AIDS Patient Care STDS. 2006 Nov;20(11):745-59
pubmed: 17134349
Nature. 2007 Apr 5;446(7136):668-71
pubmed: 17410176
Eur J Clin Microbiol Infect Dis. 2011 Aug;30(8):981-7
pubmed: 21298459
Genetics. 2003 May;164(1):23-9
pubmed: 12750318
PLoS Genet. 2012 Jun;8(6):e1002783
pubmed: 22761587
Ups J Med Sci. 2014 May;119(2):149-53
pubmed: 24666223
J Antimicrob Chemother. 2014 Feb;69(2):303-8
pubmed: 24068280
PLoS One. 2016 Jan 28;11(1):e0147651
pubmed: 26821252
Nat Rev Microbiol. 2009 Jun;7(6):460-6
pubmed: 19444248
Nat Rev Microbiol. 2007 Dec;5(12):958-65
pubmed: 18007678
Lancet. 2009 Sep 5;374(9692):796-806
pubmed: 19647866
N Engl J Med. 2001 Mar 15;344(11):824-31
pubmed: 11248160
Nat Rev Genet. 2013 Apr;14(4):243-8
pubmed: 23419278
J Antimicrob Chemother. 2012 Mar;67(3):633-7
pubmed: 22127584
Dis Chest. 1949 Dec;16(6):661-6
pubmed: 15396513
Clin Microbiol Rev. 2001 Oct;14(4):933-51, table of contents
pubmed: 11585791
Nat Rev Microbiol. 2017 Nov;15(11):689-696
pubmed: 28757648
Proc Natl Acad Sci U S A. 2008 Sep 30;105(39):14918-23
pubmed: 18815368
EMBO Mol Med. 2014 Mar;6(3):372-83
pubmed: 24500695
Curr Opin Microbiol. 2014 Jun;19:83-89
pubmed: 25016172
Proc Natl Acad Sci U S A. 2014 Oct 7;111(40):14494-9
pubmed: 25246554
Science. 2016 Jan 1;351(6268):aad3292
pubmed: 26722002
Mol Biol Evol. 2015 May;32(5):1175-85
pubmed: 25618457
Antimicrob Agents Chemother. 2012 Oct;56(10):5142-8
pubmed: 22825115
PLoS Pathog. 2013;9(4):e1003300
pubmed: 23593006
Sci Transl Med. 2013 Sep 25;5(204):204ra132
pubmed: 24068739
Sci Transl Med. 2014 Nov 12;6(262):262ra156
pubmed: 25391482
PLoS Pathog. 2010 Jan 22;6(1):e1000735
pubmed: 20107608
Nat Commun. 2018 Feb 6;9(1):522
pubmed: 29410400
Antimicrob Agents Chemother. 2011 Oct;55(10):4530-6
pubmed: 21788458
Antimicrob Agents Chemother. 2015 Mar;59(3):1718-27
pubmed: 25583718
Cell. 2018 Jan 11;172(1-2):121-134.e14
pubmed: 29307490
Mol Ecol Resour. 2011 Sep;11(5):759-69
pubmed: 21592312
Curr Opin Microbiol. 2013 Feb;16(1):10-6
pubmed: 23395351
Mol Syst Biol. 2013 Oct 29;9:700
pubmed: 24169403
Perspect Medicin Chem. 2014 Aug 28;6:25-64
pubmed: 25232278
Genetics. 2002 Mar;160(3):823-32
pubmed: 11901104

Auteurs

Carola E H Rosenkilde (CEH)

Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, DK-2800, Lyngby, Denmark.

Christian Munck (C)

Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, DK-2800, Lyngby, Denmark.
Department of Systems Biology, Columbia University, New York, NY, USA.

Andreas Porse (A)

Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, DK-2800, Lyngby, Denmark.

Marius Linkevicius (M)

Department of Medical Biochemistry and Microbiology, Uppsala University, Box 582, SE-751 23, Uppsala, Sweden.

Dan I Andersson (DI)

Department of Medical Biochemistry and Microbiology, Uppsala University, Box 582, SE-751 23, Uppsala, Sweden.

Morten O A Sommer (MOA)

Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, DK-2800, Lyngby, Denmark. msom@bio.dtu.dk.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH